In a report released today, Reni Benjamin from JMP Securities reiterated a Buy rating on Blueprint Medicines (BPMC – Research Report), with a price target of $152.00. The company's shares closed last Thursday at $55.60, close to its 52-week low of $43.46. According to TipRanks.com, Benjamin 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.0% and a 36.1% success rate. Benjamin covers the Healthcare sector, focusing on stocks such as Deciphera Pharmaceuticals, Spectrum Pharmaceuticals, and Iovance Biotherapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Blueprint Medicines with a $79.
https://www.tipranks.com/news/blurbs/blueprint-medicines-bpmc-gets-a-buy-rating-from-jmp-securities?utm_source=advfn.com&utm_medium=referral
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Aug 2022 to Sep 2022 Click Here for more Blueprint Medicines Charts.
Blueprint Medicines (NASDAQ:BPMC)
Historical Stock Chart
From Sep 2021 to Sep 2022 Click Here for more Blueprint Medicines Charts.